DTYMK

Thymidylate kinase · P23919 · DTYMK on Sugi Atlas →

9,600 patent compounds predicted against DTYMK, 5,641 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Adenosine (SCHEMBL3194871)	0.91	4/20
SCHEMBL2166244	0.87	4/20
Adenosine (SCHEMBL531208)	0.76	4/20
Adenosine (SCHEMBL3207685)	0.69	4/20
Adenosine (SCHEMBL1549514)	0.66	4/20
Deoxythymidine_Triphosphate (SCHEMBL77831)	0.65	4/20
Deoxythymidine_Triphosphate (SCHEMBL77832)	0.65	4/20
SCHEMBL887724	0.65	4/20
SCHEMBL887725	0.65	4/20
Deoxythymidine_Triphosphate (SCHEMBL1579556)	0.65	4/20
Adenosine (SCHEMBL3194327)	0.64	4/20
SCHEMBL2514765	0.64	4/20
SCHEMBL2164979	0.64	4/20
SCHEMBL2404790	0.64	4/20
Adenosine (SCHEMBL574772)	0.63	4/20
SCHEMBL1521578	0.62	4/20
SCHEMBL1520996	0.61	4/20
SCHEMBL1521023	0.61	4/20
SCHEMBL1521074	0.61	4/20
SCHEMBL1521109	0.61	4/20

Clinical trials — most relevant to DTYMK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis	PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV	PHASE1/PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	PHASE2	COMPLETED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer	PHASE1/PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study	PHASE2	UNKNOWN
M6620 (VX-970) in Selected Solid Tumors	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)	nan	UNKNOWN
Chilean Gastric Cancer Task Force (FORCE 1)	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DTYMK binder may also engage these)

Protein	Name	Similarity
P97930	—	0.998	P97930 →
Q22018	—	0.985	Q22018 →
Q3B752	—	0.985	Q3B752 →
P36590	—	0.981	P36590 →
Q5T6J7	—	0.975	Q5T6J7 →
Q99LC3	—	0.974	Q99LC3 →
Q0WW55	—	0.974	Q0WW55 →
COASY	Bifunctional coenzyme A synthase	0.973	landscape →
Q8BH55	—	0.973	Q8BH55 →
A1ZB29	—	0.973	A1ZB29 →
Q5RCH4	—	0.971	Q5RCH4 →
O81852	—	0.971	O81852 →
P00572	—	0.970	P00572 →
Q91YL3	—	0.970	Q91YL3 →
Q5ZIB9	—	0.969	Q5ZIB9 →
P17571	—	0.969	P17571 →
O48905	—	0.968	O48905 →
Q80UN9	—	0.968	Q80UN9 →
P27278	—	0.968	P27278 →
Q4WN24	—	0.967	Q4WN24 →
Q07G10	—	0.967	Q07G10 →
Q0MQB6	—	0.967	Q0MQB6 →
A3KMP2	—	0.967	A3KMP2 →
Q29RK2	—	0.967	Q29RK2 →
P0CB89	—	0.967	P0CB89 →
Q9H3H1	—	0.967	Q9H3H1 →
Q0MQB7	—	0.967	Q0MQB7 →
Q8L785	—	0.967	Q8L785 →
P57106	—	0.966	P57106 →
Q5R5P3	—	0.966	Q5R5P3 →